Scalable Solutions Through kojoX™: Building A Biomanufacturing Ecosystem For Supply Agility Starts As Early As Cell Line Development

By Charles Heise, Ph.D., Associate Director, Bioprocessing Strategy & Development, FUJIFILM Biotechnologies

With the global demand for biopharmaceuticals potentially outstripping current capacity, significant investments are being made worldwide to expand the biomanufacturing capabilities of CDMOs. At FUJIFILM Biotechnologies, we know that simply building new facilities isn't enough to solve the industry's complex supply chain challenges. That's why our unprecedented capital investment of over $8 billion to expand capacity is just one part of our strategy to improve patient access.

To go beyond simple expansion, we’ve developed a holistic, globally harmonized operational ecosystem called kojoX. This system is designed for an era where speed, cost efficiency, and market responsiveness are critical.

Through kojoX, we offer our partners future-ready solutions for biopharmaceutical production. A core component of this is our innovative MaruX™ continuous bioprocessing system. MaruX™ seamlessly integrates our powerful ApolloX™ cell line development solutions with the award-winning SymphonX™ purification system. This integration ensures a streamlined process from start to finish.

Furthermore, our kojoX ecosystem provides access to modular, scalable manufacturing capacity. This allows production to expand effortlessly across our global network, ensuring we can meet demand as it grows.